Evidence map›Paper›PMID 40808867›Full record

ArticleSexual medicine2025

Hinokiflavone alleviates high-fat diet-induced erectile dysfunction via the EGFR/PI3K/Akt/eNOS signaling pathway.

Peng-Chao Gao, Xiao-Hui Tan, Man-Cheng Xia, Ke-Fan Li, Fang-Zhou Zhao, Hong-Gang Ying, Zhuo Zhou, Yi-Ming Yuan, Tie-Gui Nan, Rui-Li Guan

Abstract read
In one paragraph

Article in Sexual medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peng-Chao GaoDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Xiao-Hui TanDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Man-Cheng XiaDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Ke-Fan LiDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Fang-Zhou ZhaoDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Hong-Gang YingDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Zhuo ZhouDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Yi-Ming YuanDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.
Tie-Gui NanState Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, PR China.
Rui-Li GuanDepartment of Urology, Peking University First Hospital, Beijing 100034, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Erectile dysfunction (ED) is a significant health issue affecting the global male population, with a complex and multifaceted etiology. High-fat diet (HFD) is known to impair endothelial function and promote the development of ED. Hinokiflavone (HINO), a naturally occurring biflavonoid, has garnered attention for its notable antioxidant and anti-inflammatory activities, suggesting its potential therapeutic role in treating ED. Aim: This study aims to investigate the therapeutic effects and underlying mechanisms of HINO in HFD-induced ED. Methods: Network pharmacology and molecular dynamics simulation were employed to predict relevant targets and analyze their binding kinetics. Rat corpus cavernosum endothelial cells (RCCECs) were treated with palmitic acid Outcomes: The primary outcomes were the target genes and pathways associated with HINO and the evaluation of its therapeutic potential in HFD-induced ED. Results: Bioinformatics analyses identified the epidermal growth factor receptor (EGFR) and protein kinase B (Akt) as key molecular targets of HINO. Treatment with HINO promoted RCCEC proliferation, enhanced antioxidant activities, and increased nitric oxide production. The administration of HINO ameliorated erectile dysfunction, improved serum lipid profiles, and reduced oxidative stress in HFD-fed rats. The protective effects of HINO against endothelial dysfunction and impaired cell viability were mediated through modulation of the EGFR/PI3K/Akt/eNOS signaling pathway. Clinical Translation: The results provide a strong rationale for further investigation of HINO as a novel therapeutic agent for ED, with promising implications for future clinical applications. Strengths and Limitations: In this study, we found that HINO could mitigate HFD-induced ED. Limitations of the study include that the alternative mechanisms of HINO were not fully explored in these settings. Conclusions: Our findings underscore the pharmacological properties of HINO in the management of ED, particularly through the modulation of critical targets such as EGFR.

Indexed as

EGFRerectile dysfunctionhigh-fat diethinokiflavonemolecular dynamics simulations

Identifiers

PMID40808867
PMCPMC12341904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.